Thinking of joining a study?

Register your interest

Become a volunteer?

NCT03740503 | RECRUITING | Cancer

Genomic Investigation of Unusual Responders
Sponsor:

University Health Network, Toronto

Brief Summary:

Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and/or other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.

Condition or disease

Cancer

Breast Cancer

Non-small Cell Lung Cancer

Colorectal Cancer

Genitourinary Cancer

Gynecological Cancer

Upper Aerodigestive Tract Cancer

Pancreatobiliary Gastrointestinal Cancer

Melanoma (Skin)

Rare Cancer

Carcinoma of Unknown Primary

Study Type : OBSERVATIONAL
Estimated Enrollment : 100 participants
Official Title : Genomic Investigation of Unusual Responders
Actual Study Start Date : 2013-11-01
Estimated Primary Completion Date : 2025-11
Estimated Study Completion Date : 2025-11

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. The patient must have either an exceptionally good or poor response to treatment, as indicated by their treating physician.
  • 1. The exact definition of this is adaptable to the disease but a suggested guideline is a Complete Response, Partial Response or progression free interval of at least 6 months
  • 2. Exceptionally poor response includes patients who were expected to respond favourably to a treatment but instead responded poorly (e.g dramatic tumor growth or death)
  • 2. The patient must have sufficient archival tumor available for sequencing.
  • 3. Deceased patients will also be considered for analysis (up to 30 patients per year) if they meet at least one of the following requirements
    • a)) Patients who have archival tissue stored within the UHN Laboratory Medicine Program who have had a consent waiver granted by the REB to access the tissue.
    • b) Patients who have archival tissue banked for further research within the UHN Biospecimen Sciences Program
    • Exclusion Criteria:
    • * None
Genomic Investigation of Unusual Responders

Location Details

NCT03740503

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

Canada, Ontario

Princess Margaret Cancer Centre

Toronto, Ontario, Canada, M5G 2M9